GlobeNewswire

LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
23/12/2025
Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company [...]
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
23/12/2025
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by [...]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
23/12/2025
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top- [...]
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The [...]
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/12/2025
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
22/12/2025
Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“ [...]
Celularity Announces Closing of Financing Transactions
22/12/2025
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the [...]
Alvotech’s Financial Calendar for 2026
22/12/2025
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the [...]
Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded.
22/12/2025
Worcester, MA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar ® is proud to report; Following its first of its kind court victory on behalf of Vystar Corp. (“Vystar”) against EMA Financial, [...]
Vivos Inc Summarizes Progress in its Animal Therapy Division
22/12/2025
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary [...]
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
22/12/2025
WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 [...]
Sanofi: Information concerning the total number of voting rights and shares - November 2025
22/12/2025
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2025
22/12/2025
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
EUROBIO SCIENTIFIC : REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES
22/12/2025
REMPLACEMENT D’UN COMMISSAIRE AUX COMPTES Paris, le 22 décembre 2025 – 18h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce [...]
EUROBIO SCIENTIFIC: REPLACEMENT OF A STATUTORY AUDITOR
22/12/2025
REPLACEMENT OF A STATUTORY AUDITOR Paris, December 22, 2025 – 6:00 pm Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, announces the replacement of one [...]
NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
22/12/2025
Ghent, Belgium, Dec. 22, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, [...]
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
22/12/2025
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY [...]
Le brevet pour le masitinib dans le traitement de la drépanocyose a été officiellement accordé aux Etats-Unis avec une protection jusqu'en 2040
22/12/2025
COMMUNIQUE DE PRESSE LE BREVET POUR LE MASITINIB DANS LE TRAITEMENT DE LA DRÉPANOCYOSE A ÉTÉ OFFICIELLEMENT ACCORDÉ AUX ÉTATS-UNIS AVEC UNE PROTECTION JUSQU'EN 2040 CETTE DÉCISION RENFORCE LE PORTEFEUILLE DE PROPRIÉTÉ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum